Health Care & Life Sciences » Biotechnology | Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Inc. | Mutual Funds

Mutual Funds that own Vertex Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Vanguard Health Care Fund
7,354,517
2.88%
-587,805
2.7%
06/30/2018
Vanguard Total Stock Market Index Fund
6,405,404
2.5%
27,808
0.16%
07/31/2018
Fidelity Contrafund
5,198,420
2.02%
346,167
0.72%
07/31/2018
T Rowe Price Blue Chip Growth Fund
5,151,400
2.02%
-195,000
1.66%
06/30/2018
Vanguard 500 Index Fund
4,614,982
1.81%
6,640
0.19%
07/31/2018
T Rowe Price Growth Stock Fund
4,405,475
1.72%
-736,100
1.45%
06/30/2018
American Funds Growth Fund of America
3,665,557
1.43%
583,957
0.37%
06/30/2018
American Funds Fundamental Investors
3,609,727
1.41%
715,400
0.73%
06/30/2018
SPDR S&P 500 ETF
2,817,478
1.1%
32,550
0.19%
09/06/2018
T Rowe Price Health Sciences Fund
2,516,690
0.99%
45,700
3.64%
06/30/2018

About Vertex Pharmaceuticals

View Profile
Address
50 Northern Avenue
Boston Massachusetts 02210
United States
Employees -
Website http://www.vrtx.com
Updated 07/08/2019
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington's disease and multiple sclerosis. The company was founded by Joshua S.